Rebecca Suzanne Leenheer, MD | |
303 Mulberry St Ne, Albuquerque, NM 87106-4739 | |
(505) 243-9739 | |
(505) 842-0650 |
Full Name | Rebecca Suzanne Leenheer |
---|---|
Gender | Female |
Speciality | Ophthalmology |
Experience | 18 Years |
Location | 303 Mulberry St Ne, Albuquerque, New Mexico |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1033397575 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207W00000X | Ophthalmology | MD2012-0769 (New Mexico) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Family Eye Care/children's Eye Center Of New Mexico, P.c. | 5395838056 | 3 |
News Archive
A new study reveals that humans use different neural mechanisms for determining criminal responsibility and assigning an appropriate punishment.
Partial nephrectomy and radical nephrectomy provide comparable cancer control for T1b renal cell carcinoma, yet use of the less radical approach has remained limited in the USA over recent years, study results show.
InterMune, Inc. (Nasdaq: ITMN) today announced that it will be collaborating with National Jewish Health(R)( )investigators in order to help further the research of inherited genetic factors that may play a role in idiopathic pulmonary fibrosis (IPF). InterMune will provide researchers at National Jewish with access to DNA collected from patients who participated in the Company's Phase 3 clinical trials in IPF for both pirfenidone (CAPACITY trials) and Actimmune(R) (interferon gamma-1b) (INSPIRE).
Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the treatment and prevention of infectious and progressive respiratory diseases, today announced that it has been awarded a grant for $2.2 million from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), aimed at advancing the development of novel influenza therapeutics for the treatment of seasonal and pandemic influenza.
› Verified 4 days ago
Entity Name | Unm Medical Group Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1831218627 PECOS PAC ID: 4981795267 Enrollment ID: O20070801000589 |
News Archive
A new study reveals that humans use different neural mechanisms for determining criminal responsibility and assigning an appropriate punishment.
Partial nephrectomy and radical nephrectomy provide comparable cancer control for T1b renal cell carcinoma, yet use of the less radical approach has remained limited in the USA over recent years, study results show.
InterMune, Inc. (Nasdaq: ITMN) today announced that it will be collaborating with National Jewish Health(R)( )investigators in order to help further the research of inherited genetic factors that may play a role in idiopathic pulmonary fibrosis (IPF). InterMune will provide researchers at National Jewish with access to DNA collected from patients who participated in the Company's Phase 3 clinical trials in IPF for both pirfenidone (CAPACITY trials) and Actimmune(R) (interferon gamma-1b) (INSPIRE).
Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the treatment and prevention of infectious and progressive respiratory diseases, today announced that it has been awarded a grant for $2.2 million from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), aimed at advancing the development of novel influenza therapeutics for the treatment of seasonal and pandemic influenza.
› Verified 4 days ago
Entity Name | Family Eye Care/children's Eye Center Of New Mexico, P.c. |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1578574828 PECOS PAC ID: 5395838056 Enrollment ID: O20070911000631 |
News Archive
A new study reveals that humans use different neural mechanisms for determining criminal responsibility and assigning an appropriate punishment.
Partial nephrectomy and radical nephrectomy provide comparable cancer control for T1b renal cell carcinoma, yet use of the less radical approach has remained limited in the USA over recent years, study results show.
InterMune, Inc. (Nasdaq: ITMN) today announced that it will be collaborating with National Jewish Health(R)( )investigators in order to help further the research of inherited genetic factors that may play a role in idiopathic pulmonary fibrosis (IPF). InterMune will provide researchers at National Jewish with access to DNA collected from patients who participated in the Company's Phase 3 clinical trials in IPF for both pirfenidone (CAPACITY trials) and Actimmune(R) (interferon gamma-1b) (INSPIRE).
Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the treatment and prevention of infectious and progressive respiratory diseases, today announced that it has been awarded a grant for $2.2 million from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), aimed at advancing the development of novel influenza therapeutics for the treatment of seasonal and pandemic influenza.
› Verified 4 days ago
Mailing Address | Practice Location Address |
---|---|
Rebecca Suzanne Leenheer, MD 303 Mulberry St Ne, Albuquerque, NM 87106-4739 Ph: (505) 243-9739 | Rebecca Suzanne Leenheer, MD 303 Mulberry St Ne, Albuquerque, NM 87106-4739 Ph: (505) 243-9739 |
News Archive
A new study reveals that humans use different neural mechanisms for determining criminal responsibility and assigning an appropriate punishment.
Partial nephrectomy and radical nephrectomy provide comparable cancer control for T1b renal cell carcinoma, yet use of the less radical approach has remained limited in the USA over recent years, study results show.
InterMune, Inc. (Nasdaq: ITMN) today announced that it will be collaborating with National Jewish Health(R)( )investigators in order to help further the research of inherited genetic factors that may play a role in idiopathic pulmonary fibrosis (IPF). InterMune will provide researchers at National Jewish with access to DNA collected from patients who participated in the Company's Phase 3 clinical trials in IPF for both pirfenidone (CAPACITY trials) and Actimmune(R) (interferon gamma-1b) (INSPIRE).
Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the treatment and prevention of infectious and progressive respiratory diseases, today announced that it has been awarded a grant for $2.2 million from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), aimed at advancing the development of novel influenza therapeutics for the treatment of seasonal and pandemic influenza.
› Verified 4 days ago
Ana G Huaman, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3901 Georgia St Ne Ste G-2, Albuquerque, NM 87110 Phone: 505-266-8200 Fax: 505-256-7565 | |
John E Graham, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 5400 Gibson Blvd Se, Albuquerque, NM 87108 Phone: 505-262-3937 Fax: 505-262-7147 | |
Dr. Michael Scott Seligson, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 4343 Pan American Fwy Ne, Ste. 224, Albuquerque, NM 87107 Phone: 505-344-5400 Fax: 505-344-5404 | |
Charles Chiang, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 5757 Harper Dr Ne, Albuquerque, NM 87109 Phone: 505-888-5757 Fax: 505-865-0160 | |
Dr. Ian Abban Thompson, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 4411 The 25 Way Ne Ste 325, Albuquerque, NM 87109 Phone: 505-823-4411 Fax: 505-343-6085 | |
Robert K Rothberg, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 5150 Journal Center Blvd Ne, Albuquerque, NM 87109 Phone: 505-262-3937 Fax: 505-262-3366 |